| ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025 |
Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , May 8, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal second quarter ended March 31, 2025. |
prnewswire.com |
2025-05-08 11:00:00 |
Czytaj oryginał (ang.) |
| Shareholders of ESSA Pharma Inc. Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX |
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138642&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-03-25 18:15:00 |
Czytaj oryginał (ang.) |
| ESSA Pharma Inc. Class Action: Levi & Korsinsky Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX |
NEW YORK , March 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") (NASDAQ: EPIX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of ESSA Pharma Inc. investors who were adversely affected by alleged securities fraud between December 12, 2023 and October 31, 2024. |
prnewswire.com |
2025-03-25 14:52:00 |
Czytaj oryginał (ang.) |
| EPIX Deadline Today: Rosen Law Firm Urges ESSA Pharma Inc. (NASDAQ: EPIX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights |
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of ESSA Pharma Inc. (NASDAQ: EPIX) securities between December 12, 2023 and October 31, 2024, inclusive (the “Class Period”). The lawsuit describes ESSA as a “clinical stage pharmaceutical company that focuses on the development of small molecular drugs for the treatment of prostate cancer.” For more information, submit a form, ema. |
businesswire.com |
2025-03-25 13:18:00 |
Czytaj oryginał (ang.) |
| ESSA Pharma Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX |
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138572&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-03-25 13:15:00 |
Czytaj oryginał (ang.) |
| EPIX DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important March 25 Deadline in Securities Class Action - EPIX |
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ESSA Pharma Inc. (NASDAQ:EPIX) between December 12, 2023 and October 31, 2024, inclusive (the "Class Period"), of the important March 25, 2025 lead plaintiff deadline. SO WHAT: If you purchased ESSA Pharma Inc. securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. |
accessnewswire.com |
2025-03-25 12:45:00 |
Czytaj oryginał (ang.) |
| Investors who lost money on ESSA Pharma Inc.(EPIX) should contact Levi & Korsinsky about pending Class Action - EPIX |
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138559&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-03-25 12:30:00 |
Czytaj oryginał (ang.) |
| FINAL REMINDER EPIX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts ESSA Pharma Inc. Investors to Participate in the Class Action Lawsuit! |
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:EPIX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ESSA securities between December 12, 2023 and October 31, 2024, both dates inclusive (the "Class Period"). |
accessnewswire.com |
2025-03-25 12:00:00 |
Czytaj oryginał (ang.) |
| ESSA Pharma Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – EPIX |
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138426&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-03-24 21:45:00 |
Czytaj oryginał (ang.) |
| ESSA Pharma Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2025 Deadline to file Lead Plaintiff Motion |
Investors can contact the law firm at no cost to learn more about recovering their losses |
globenewswire.com |
2025-03-24 21:33:00 |
Czytaj oryginał (ang.) |
| EPIX LAWSUIT ALERT: Levi & Korsinsky Notifies ESSA Pharma Inc. Investors of a Class Action Lawsuit and Upcoming Deadline |
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138382&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-03-24 19:30:00 |
Czytaj oryginał (ang.) |
| Shareholders of ESSA Pharma Inc. Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX |
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138345&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-03-24 18:15:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of ESSA Pharma Inc. (EPIX) Shareholders |
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138264&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-03-24 12:30:00 |
Czytaj oryginał (ang.) |
| FINAL EPIX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds ESSA Pharma Inc. Investors to Join the Class Action Lawsuit! |
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:EPIX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ESSA securities between December 12, 2023 and October 31, 2024, both dates inclusive (the "Class Period"). |
accessnewswire.com |
2025-03-24 12:00:00 |
Czytaj oryginał (ang.) |
| The Gross Law Firm Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX |
NEW YORK , March 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX). Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. |
prnewswire.com |
2025-03-24 07:45:00 |
Czytaj oryginał (ang.) |
| ESSA Pharma Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights – EPIX |
NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") (NASDAQ: EPIX) of a class action securities lawsuit. |
globenewswire.com |
2025-03-24 07:35:00 |
Czytaj oryginał (ang.) |
| Shareholders that lost money on ESSA Pharma Inc.(EPIX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More |
NEW YORK, NY / ACCESS Newswire / March 23, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138134&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-03-23 18:30:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in ESSA Pharma Inc. Lawsuit - EPIX |
NEW YORK, NY / ACCESS Newswire / March 23, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138123&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-03-23 16:53:00 |
Czytaj oryginał (ang.) |
| EPIX IMPORTANT DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important March 25 Deadline in Securities Class Action - EPIX |
NEW YORK, March 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ESSA Pharma Inc. (NASDAQ: EPIX) between December 12, 2023 and October 31, 2024, inclusive (the “Class Period”), of the important March 25, 2025 lead plaintiff deadline. |
globenewswire.com |
2025-03-23 16:46:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in ESSA Pharma Inc. Lawsuit - EPIX |
NEW YORK, NY / ACCESS Newswire / March 23, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=138080&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-03-23 12:23:00 |
Czytaj oryginał (ang.) |
| Investors who Lost Money on ESSA Pharma Inc. (EPIX) Should Contact Levi & Korsinsky about Pending Class Action - EPIX |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=132805&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-27 18:30:00 |
Czytaj oryginał (ang.) |
| EPIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ESSA Pharma Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit |
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ESSA Pharma Inc. (“ESSA” or “the Company”) (NASDAQ: EPIX) and certain of its officers. |
globenewswire.com |
2025-02-27 18:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=132781&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-27 16:00:00 |
Czytaj oryginał (ang.) |
| ROSEN, A LEADING LAW FIRM, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EPIX |
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ESSA Pharma Inc. (NASDAQ: EPIX) between December 12, 2023 and October 31, 2024, inclusive (the “Class Period”), of the important March 25, 2025 lead plaintiff deadline. |
globenewswire.com |
2025-02-27 15:36:00 |
Czytaj oryginał (ang.) |
| Investors who lost money on ESSA Pharma Inc. (EPIX) should contact Levi & Korsinsky about pending Class Action - EPIX |
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") (NASDAQ: EPIX) of a class action securities lawsuit. |
globenewswire.com |
2025-02-27 14:36:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=132708&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-27 12:15:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against ESSA Pharma Inc. |
LOS ANGELES, CA / ACCESS Newswire / February 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:EPIX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 12, 2023 and October 31, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 25, 2025. |
accessnewswire.com |
2025-02-27 12:00:00 |
Czytaj oryginał (ang.) |
| The Gross Law Firm Notifies Shareholders of ESSA Pharma Inc.(EPIX) of a Class Action Lawsuit and an Upcoming Deadline |
NEW YORK , Feb. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX). Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. |
prnewswire.com |
2025-02-27 07:45:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies ESSA Pharma Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - EPIX |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=132570&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-26 22:45:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against ESSA Pharma Inc. and Certain Officers - EPIX |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX) and certain officers. The class action, filed in the United States District Court for the Eastern District of Wisconsin, and docketed under 25-cv-00124, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired ESSA securities between December 12, 2023 and October 31, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. |
accessnewswire.com |
2025-02-26 22:00:00 |
Czytaj oryginał (ang.) |
| The Gross Law Firm Notifies ESSA Pharma Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – EPIX |
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX). |
globenewswire.com |
2025-02-26 15:28:00 |
Czytaj oryginał (ang.) |
| Shareholders of ESSA Pharma Inc. Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=132452&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-26 13:45:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against ESSA Pharma Inc. and Certain Officers - EPIX |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX) and certain officers. The class action, filed in the United States District Court for the Eastern District of Wisconsin, and docketed under 25-cv-00124, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired ESSA securities between December 12, 2023 and October 31, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. |
accessnewswire.com |
2025-02-26 13:15:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in ESSA Pharma Inc. Lawsuit - EPIX |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=132402&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-26 12:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA Pharma |
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ESSA Pharma To Contact Him Directly To Discuss Their Options |
globenewswire.com |
2025-02-26 12:28:00 |
Czytaj oryginał (ang.) |
| EPIX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ESSA Pharma Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:EPIX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ESSA securities between December 12, 2023 and October 31, 2024, both dates inclusive (the "Class Period"). |
accessnewswire.com |
2025-02-26 12:00:00 |
Czytaj oryginał (ang.) |
| ESSA Pharma Inc. Class Action: Levi & Korsinsky Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 – EPIX |
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=132240&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-25 21:45:00 |
Czytaj oryginał (ang.) |
| March 25, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against EPIX |
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=132220&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-25 20:00:00 |
Czytaj oryginał (ang.) |
| ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EPIX |
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ESSA Pharma Inc. (NASDAQ:EPIX) between December 12, 2023 and October 31, 2024, inclusive (the "Class Period"), of the important March 25, 2025 lead plaintiff deadline. SO WHAT: If you purchased ESSA Pharma Inc. securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. |
accessnewswire.com |
2025-02-25 19:30:00 |
Czytaj oryginał (ang.) |
| ESSA Pharma Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights – EPIX |
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=132193&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-25 19:05:00 |
Czytaj oryginał (ang.) |
| ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024 |
Company has initiated a process to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Dec. 17, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company that, prior to the discontinuation of its clinical trials and preclinical and other development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2024. "We recently made the difficult decision to terminate the clinical development of masofaniten, and withdraw the related IND and CTAs, based on an interim analysis of the data from the Phase 2 combination study, concluding that masofaniten combined with enzalutamide was unlikely to meet its primary endpoint," said David Parkinson, MD, President and CEO of ESSA. |
prnewswire.com |
2024-12-17 09:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX |
NEW YORK , Dec. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-12-03 21:23:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX |
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-11-27 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX |
NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-11-26 18:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX |
NEW YORK , Nov. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-11-25 22:05:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX |
NEW YORK CITY, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-11-20 18:30:00 |
Czytaj oryginał (ang.) |
| Lost Money on ESSA Pharma Inc.(EPIX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation |
NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens. |
accesswire.com |
2024-11-19 00:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX |
NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-11-18 23:52:00 |
Czytaj oryginał (ang.) |
| EPIX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your ESSA Pharma Inc. investment |
NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens. |
accesswire.com |
2024-11-18 09:25:00 |
Czytaj oryginał (ang.) |
| ATTENTION ESSA Pharma Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights |
NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens. |
accesswire.com |
2024-11-16 21:31:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX |
NEW YORK CITY, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-11-16 14:00:00 |
Czytaj oryginał (ang.) |
| ATTENTION ESSA Pharma Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights |
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens. |
accesswire.com |
2024-11-14 19:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX |
NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-11-14 18:30:00 |
Czytaj oryginał (ang.) |
| EPIX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ESSA Pharma Inc. |
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens. |
accesswire.com |
2024-11-14 09:30:00 |
Czytaj oryginał (ang.) |
| ESSA Pharma Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - EPIX |
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens. |
accesswire.com |
2024-11-12 19:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX |
NEW YORK CITY, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-11-12 18:15:00 |
Czytaj oryginał (ang.) |
| Lost Money on ESSA Pharma Inc.(EPIX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky |
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens. |
accesswire.com |
2024-11-12 09:30:00 |
Czytaj oryginał (ang.) |
| EPIX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ESSA Pharma Inc. |
NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens. |
accesswire.com |
2024-11-11 09:30:00 |
Czytaj oryginał (ang.) |
| EPIX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your ESSA Pharma Inc. investment |
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens. |
accesswire.com |
2024-11-08 09:25:00 |
Czytaj oryginał (ang.) |
| EPIX STOCK ALERT: Levi & Korsinsky Notifies ESSA Pharma Inc. Investors of an Ongoing Investigation |
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens. |
accesswire.com |
2024-11-06 12:30:00 |
Czytaj oryginał (ang.) |